ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO BURLO GAROFOLO

Their core work

IRCCS Burlo Garofolo is a publicly funded scientific hospital (IRCCS) in Trieste, Italy, specializing in maternal and child health. They conduct clinical research on paediatric diseases, neonatal care, and the effects of environmental exposures on child neurodevelopment. Their work bridges clinical care with research, contributing expertise in paediatric clinical trials, biomonitoring, and radiation protection in medical settings.

What they specialise in

How they've shifted over time

Their earliest H2020 work (2017) focused on understanding how environmental exposures cause neurodevelopmental disorders, using biomonitoring and genomic approaches (GWAS, EWAS). By 2018-2020, they shifted toward clinical infrastructure — building networks for paediatric drug development and contributing to radiation safety standards in medicine. The trajectory moves from basic exposure science toward clinical translation and care delivery frameworks.

Moving from understanding disease causes toward building the clinical trial infrastructure needed to develop better treatments for children.

How they like to work

Burlo Garofolo operates exclusively as a contributing partner or third party — never as coordinator. With 98 unique partners across 24 countries from just 3 projects, they participate in very large consortia (c4c alone is a massive pan-European network). This suggests they are valued for specific clinical expertise rather than project management capacity.

Despite only 3 projects, they have connected with 98 unique partners across 24 countries, reflecting their participation in large-scale pan-European health networks. Their reach is broad but driven by the large consortia they join rather than bilateral relationships.

What sets them apart

As a dedicated maternal-child IRCCS (scientific hospital), Burlo Garofolo offers something rare: direct access to paediatric patient populations combined with research infrastructure. For any consortium needing a clinical site for children's health research — whether drug trials, exposure studies, or radiation safety — they provide both the scientific capacity and the patient base. Their location in Trieste also positions them as a bridge to Central/Eastern European populations.

Highlights from their portfolio

• c4c
  Part of one of Europe's largest paediatric clinical trial networks, connecting regulatory expertise with real-world clinical sites for children's medicines.
• NEUROSOME
  Their largest funded project (EUR 258K), combining genomics, biomonitoring, and neuroscience to understand environmental causes of childhood neurodevelopmental disorders.